[go: up one dir, main page]

ATE432262T1 - Pyrazolphenylderivate als ppar-aktivatoren - Google Patents

Pyrazolphenylderivate als ppar-aktivatoren

Info

Publication number
ATE432262T1
ATE432262T1 AT05735100T AT05735100T ATE432262T1 AT E432262 T1 ATE432262 T1 AT E432262T1 AT 05735100 T AT05735100 T AT 05735100T AT 05735100 T AT05735100 T AT 05735100T AT E432262 T1 ATE432262 T1 AT E432262T1
Authority
AT
Austria
Prior art keywords
pyrazolephenyl
derivatives
ppar activators
ppar
compounds
Prior art date
Application number
AT05735100T
Other languages
English (en)
Inventor
Jean Ackermann
Johannes Aebi
Alfred Binggeli
Uwe Grether
Georges Hirth
Bernd Kuhn
Hans-Peter Maerki
Markus Meyer
Peter Mohr
Matthew Wright
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE432262T1 publication Critical patent/ATE432262T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
AT05735100T 2004-04-28 2005-04-20 Pyrazolphenylderivate als ppar-aktivatoren ATE432262T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04101792 2004-04-28
PCT/EP2005/004199 WO2005105754A1 (en) 2004-04-28 2005-04-20 Pyrazole phenyl derivatives as ppar activators

Publications (1)

Publication Number Publication Date
ATE432262T1 true ATE432262T1 (de) 2009-06-15

Family

ID=34965271

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05735100T ATE432262T1 (de) 2004-04-28 2005-04-20 Pyrazolphenylderivate als ppar-aktivatoren

Country Status (14)

Country Link
US (3) US20050245589A1 (de)
EP (1) EP1742923B1 (de)
JP (1) JP4733692B2 (de)
KR (1) KR100815691B1 (de)
CN (1) CN1946698B (de)
AT (1) ATE432262T1 (de)
AU (1) AU2005238163A1 (de)
BR (1) BRPI0510451A (de)
CA (1) CA2563461C (de)
DE (1) DE602005014629D1 (de)
ES (1) ES2324674T3 (de)
MX (1) MXPA06012093A (de)
RU (1) RU2384573C2 (de)
WO (1) WO2005105754A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090066289A (ko) 2006-09-08 2009-06-23 로드아일랜드하스피틀 알코올 유발성 뇌 질환의 치료, 예방 및 역행
EP2061484B1 (de) 2006-09-08 2012-11-07 Rhode Island Hospital Behandlung, vorbeugung und umkehrung alkohol-induzierter lebererkrankungen
AU2007341981A1 (en) 2006-12-29 2008-07-10 The Salk Institute For Biological Studies Methods for enhancing exercise performance
JP5753784B2 (ja) 2008-10-10 2015-07-22 ダラ・バイオサイエンシズ，インコーポレイテッド スピカマイシン誘導体を用いて疼痛を治療又は予防する方法
JP2013538215A (ja) 2010-08-31 2013-10-10 エスエヌユー アールアンドディービー ファウンデーション ＰＰＡＲδアゴニストの胎児再プログラミング用途
WO2015061481A1 (en) 2013-10-23 2015-04-30 Dara Biosciences, Inc. Methods of treating liquid tumors using compositions comprising spicamycin derivatives

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1206457T3 (da) * 1999-08-27 2004-02-16 Lilly Co Eli Biaryl-oxa(thia)zolderivater og deres anvendelse som modulatorer PPAP'ER
JP2003171275A (ja) * 2001-12-11 2003-06-17 Sumitomo Pharmaceut Co Ltd ＰＰＡＲδアゴニスト
JP2003292439A (ja) * 2002-02-04 2003-10-15 Sumitomo Pharmaceut Co Ltd 新規ピロール誘導体からなるｐｐａｒ活性化剤
GB0214139D0 (en) * 2002-06-19 2002-07-31 Glaxo Group Ltd Chemical compounds
EP1585733A1 (de) * 2003-01-06 2005-10-19 Eli Lilly And Company Heterozyklische ppar modulatoren

Also Published As

Publication number Publication date
US20050245589A1 (en) 2005-11-03
US20110237640A1 (en) 2011-09-29
CA2563461A1 (en) 2005-11-10
RU2006141686A (ru) 2008-06-10
CN1946698A (zh) 2007-04-11
CN1946698B (zh) 2010-12-01
AU2005238163A1 (en) 2005-11-10
US20100035953A1 (en) 2010-02-11
EP1742923B1 (de) 2009-05-27
RU2384573C2 (ru) 2010-03-20
ES2324674T3 (es) 2009-08-12
JP4733692B2 (ja) 2011-07-27
KR100815691B1 (ko) 2008-03-20
EP1742923A1 (de) 2007-01-17
CA2563461C (en) 2012-12-11
MXPA06012093A (es) 2007-01-25
WO2005105754A1 (en) 2005-11-10
BRPI0510451A (pt) 2007-10-30
DE602005014629D1 (de) 2009-07-09
KR20070002071A (ko) 2007-01-04
JP2007534715A (ja) 2007-11-29

Similar Documents

Publication Publication Date Title
EA201001669A1 (ru) Замещенные пиримидин-5-карбоксамиды 281
EA201001733A1 (ru) Производные тиенопиридона в качестве активаторов амр-активированной протеинкиназы (амрк)
NZ592425A (en) Isoindoline compounds for use in the treatment of cancer
TW200700069A (en) Benzothiazole, thiazolopyridine, benzooxazole and oxazolopyridine derivatives
MA37891A1 (fr) Alcoxypyrazoles comme activateurs de guanylate cyclase soluble
MY138906A (en) Phenyl derivatives as ppar agonists
TW200716547A (en) Piperidin-4-yl-amide derivatives
MY157116A (en) Novel seh inhibitors and their use
NO20090979L (no) (3-amino-1,2,3,4-tetrahydro-9H-karbazol-9-yl)-eddiksyrederivater
EA200870302A1 (ru) 1,3-диоксанкарбоновые кислоты
MY148988A (en) Terphenyl derivatives for treatment of alzheimer's disease
MX2009012613A (es) Tiazoles substituidos por heteroarilo y su uso como agentes antivirales.
EA200802223A1 (ru) 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90
MX2009009238A (es) Nuevos inhibidores de fosfodiesterasa.
NO20064982L (no) 1,3,4-oksadiazol-2-oner som PPAR delta modulatorer og anvendelse derav
DE602004008959D1 (de) Benzoäbüä1,4üdioxepinderivate
MX2010001020A (es) Derivados de pirimidina utiles para el tratamiento de condiciones inflamatorias o alergicas.
DE602007001463D1 (de) Pyrimidin-, chinazolin-, pteridin- und triazinderivate
TN2009000483A1 (fr) Derives de 7-alkynyl-1-8-naphthyridones, leur preparation et leur application en therapeutique
IN2012DN02502A (de)
TW200616979A (en) Non-nucleoside reverse transcriptase inhibitors
MY143568A (en) 11b-hsd1 inhibitors for the treatment of diabetes
ATE492534T1 (de) 1h-indol-5-ylpiperazin-1-ylmethanonderivate
ATE512142T1 (de) Pyrimidin- und chinazolinderivate als modulatoren der somatostatin-rezeptor aktivität
MA32375B1 (fr) Derives de 5-hydroxymethyl-oxazolidine-2-one pour le traitement de maladies intestinales bacteriennes

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1742923

Country of ref document: EP